NBRV - Nabriva Therapeutics GAAP EPS of -$4.21 misses by $0.18 revenue of $9.15M misses by $1.53M
- Nabriva Therapeutics press release ( NASDAQ: NBRV ): Q3 GAAP EPS of -$4.21 misses by $0.18 .
- Revenue of $9.15M (+2.8% Y/Y) misses by $1.53M .
- As of September 30, 2022, Nabriva had $14.8 million in cash, cash equivalents and restricted cash. Based on its current operating plans, Nabriva expects that its existing cash resources will be sufficient to enable it to fund its operating expenses, debt service obligations and capital expenditure requirements into the first quarter of 2023.
For further details see:
Nabriva Therapeutics GAAP EPS of -$4.21 misses by $0.18, revenue of $9.15M misses by $1.53M